期刊文献+

成骨性骨转移的发生机制及其诊治现状 被引量:7

Advancement in the Research of Osteoblastic Metastasis Molecular Mechanism,Diagnosis and Treatment
下载PDF
导出
摘要 骨转移是恶性肿瘤的常见并发症,一旦发生骨转移,患者常伴有严重疼痛、病理性骨折、高钙血症及神经压迫综合症,且预后较差。骨转移是肿瘤治疗中一个严重而耗费极大的临床症状,也是近年来的研究热点之一。骨转移可分为溶骨性、成骨性及混合性骨转移。成骨性骨转移与溶骨性骨转移本质上的区别在于骨组织微环境中所释放出的细胞因子的作用不同,前者激活的细胞因子均具有促成骨作用。在临床可通过全身骨扫描、X线、CT或MRI等检查手段检测成骨性骨转移的发生。治疗成骨性骨转移不能单一应用一种方法,也不能只重视骨转移而忽视原发肿瘤的治疗,应合理选用化疗、内分泌治疗、外照射治疗、核素治疗、手术、双膦酸盐药物及止痛药物等不同的治疗方法,综合运用多学科手段治疗成骨性骨转移。 Bone is a common site of cancer metastasis. Complications of skeletal metastasis include pathological fractures, hypercaleemia, spinal cord compression, and bone pain. These conditions have a profound impact on patients" quality of life and lead to impaired mobility. Theretbre, the study of skeletal metastasis has been an important topic in carcinoma treatmenl. Bone metastasis can be classified into osteolytic, osteoblastic, and mixed, according to the primary mechanism of interference with normal bone remodeling. The main mechanism of osteoblastic metastasis involves cytokines which stimulate bone formation and osteoblast prolit^ration in the bone microenvironment. Osteoblastic metastasis can be detected by bone scanning, X-ray, CT and MRI. The treatment for osteoblastic metastasis includes chemotherapy, endocrine therapy, external radiation, internal radiation, surgery, and administration of bisphosphonates and analgesics. These therapies should be combined to achieve the best results.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2007年第19期1135-1138,共4页 Chinese Journal of Clinical Oncology
关键词 成骨性骨转移 恶性肿瘤 发生机制 诊断 治疗 Osteoblastic metastasis Malignant tumor Mechanism Diagnose Therapeutics
  • 相关文献

参考文献16

  • 1Raubenheimer EJ, Noffke CE. Pathogenesis of bone metastasis: a review[J].J Oral Pathol Med, 2006, 35(3): 129-135.
  • 2Thomas BG, Hamdy FC. Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer [J]. Prostate Cancer Prostatic Dis, 2000, 3(4): 283-285.
  • 3Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 producdon and decreased endothelin B receptor expression in advanced prostate cancer[J]. Cancer Res, 1996, 56(4): 663-668.
  • 4Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases [J]. Proc Nad Acad Sci U S A, 2003, 100(19): 10954-10959.
  • 5Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics [J]. J Clin Oncol, 2002, 20 (8): 2171 - 2180.
  • 6Chua CC, Chua BH, Chen Z, et al. TGF-betal inhibits multiple caspases induced by TNF-alpha in murine osteoblastic MC3T3E1 cells[J]. Biochim Biophys Acta, 2002, 1593(1): 1-8.
  • 7Shah AH, Tabayoyong WB, Kundu SD, et al. Suppression of rumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene dlerapy in mice[J]. Cancer Res, 2002, 62(24): 7135-7138.
  • 8Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging[J]. Ann Intern Med, 2002, 137(7): 586-597.
  • 9Chen WT, Shih TT, Chen RC, et al. Blood perfusion of vertebral lesions evaluated with gadolinium-enhanced dynamic MRI:in comparison with compression fracture and metastasis [J]. J Magn Reson Imaging, 2002, 15(3): 308-314.
  • 10Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging[J]. Invest Radiol, 2003, 38(5): 250-256.

二级参考文献12

  • 1Salmon JM,Kilpatrick SE.Pathology of skeletal metastases [J].Orthop Clin North Am,2000,31(4):537~544.
  • 2Clain A.Secondary malignant disease of bone [J].Br J Cancer,1965,19:15~29.
  • 3Delmas PD,5 Schlemmer A,Gineyts E,et al.Urinary excretion of pyridinoline cross-links correlate with bone turn over measured on iliocrsest bone biopsy in patients with vertebral osteoporosis[J].J Bone Miner Res,1991,6(1):639~644.
  • 4JJ.Body.Metastic Bone Disease:Clinical and Therapeutic Aspects.Bone,1992,3,S57-S62Paterson AHG.Bone metastases in breast cancer,prostate cancer and myeloma[J].Bone,1987,8(suppl 1):17~22.
  • 5Coleman RE,Mashiter G,Whitaker KB,et al.Bone scan flare predict successful systemic therapy for bone metastases [J].Med J Nucl,1988,29(8):1354~1359.
  • 6Lipton A,Costa L,Ail S,et al.Use of Bone Turnover for Monitoring Bone Metastases and the Respone to Therapy [J].Semin Oncol,2001,28(4 Suppl 11):54~59.
  • 7Miyamoto KK,McSherry SA,Robins SP,et al.Collagen crosslink metabolites in urine as markers of bone metastases in prostatic carcinoma[J].J Urol,1994,151(4):909~913.
  • 8Demers LM,Costa L,Chinchilli VM,et al.Biochemical markers of bone turnover in patients with metastatic bone disease[J].GlinChem,1995,41(10):1489~1494.
  • 9Berruti A,Dogliotti L,Gorzegno G,et al.Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases[J].Clin Chem,1999,45(8):1240~1247.
  • 10Niwa T,Shiobara K,Hamada T,et al.Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients [J].Clin ChimActa,1995,235(1):33~40.

共引文献557

同被引文献93

  • 1葛中泽.利用VB远程控制DEXA骨密度仪运行[J].鄂州大学学报,2004,11(4):20-22. 被引量:1
  • 2吴星火,杨述华.Paget骨病研究进展[J].国外医学(骨科学分册),2005,26(4):215-217. 被引量:5
  • 3余靖,邸立军,宛凤玲,勇威本.骨代谢生化指标和恶性肿瘤骨转移不同临床表现的关系[J].肿瘤防治研究,2006,33(5):364-367. 被引量:9
  • 4李国东,蔡郑东.转移性骨肿瘤相关分子机制研究进展[J].国际骨科学杂志,2007,28(4):239-241. 被引量:1
  • 5Kodo O, Sabokbar A, Itonaga I, et al. Interleukin-6 and interleukin-1 1 support human osteoclast formation by a RANKL-independent mechanism [J]. Bone, 2003, 32(1): 1-7.
  • 6Hong SJ, Cho KS, Cho HY, et al. A Prospective, multicenter, openlabel trial of zoledronic acid in patients with hormone refractory prostate cancer[Jl. Yonsei Med J, 2007, 48(6): 1001-08.
  • 7Ferretti G, Fabi A, Carlini P, et al. Zoledronic - acid - induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients[J]. Oncology, 2005, 69 (1): 35-7.
  • 8Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases [J]. Q J Nucl Med, 2001, 45(3): 53-64.
  • 9Peterson JJ, Ktansdorf M J, O Connor MI. Diagnosis of occult bone metastases: positron emission tomography [J]. Clin Orthop, 2003, 415(10): 120-8.
  • 10Clemens JD, Herrick MV, Singer FR, et al. Evidence that serum NTX (collagen-type Ⅰ N-telopeptides) can act as an immunochemical marker of bone resorption [J]. Clin Chem, 1997, 43(11): 2058-63.

引证文献7

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部